The Ainos Inc (OTCMKTS:AIMD) stock has been on an upward move over the past few days and has manages to clock gains of as much as 8% over the course of the past week.
On Wednesday, AIMD stock ended lower by 2.64% at $0.70 with more than 250 shares, compared to its average volume of 1.5k shares. The stock has moved within a range of $0.7000 – 0.7000 after opening the trade at $0.70.
Ainos SRNA Research Initiative Announces Milestones for mRNA Vaccine Development
As it happens, the company was in the news yesterday after it made a key announcement yesterday with regards to its mRNA vaccine. Ainos announced that it hit some early stage milestones with regards to the current development and research initiatives that it had undertaken for its mRNA vaccine. The vaccine in question is meant for tackling the deadly Delta variant of the COVID-19 virus.
The Chairman and Chief Executive Officer of Ainos, Chun-Hsien Tsai spoke about the development as well. He stated that everyone at the company was encouraged by the sort of progress that Ainos has managed in its synthetic RNA research programme.
He went on to add that in addition to the mRNA vaccine for the Delta variant of the COVID-19 virus, the company is going to be involved in the development of other vaccines as well. The excitement among investors with regards to the Ainos stock at this point is hence understandable. Investors could do well to keep an eye on it.
“We are extremely encouraged by the recent progress in our synthetic RNA research initiative since it is a major focus of our newly formed Preventive Medicine division. We are committed to developing a SARS-CoV-2 mRNA vaccine and facilitating the establishment of other synthetic RNA technology platforms,” commented Mr. Chun-Hsien Tsai, Chairman and CEO of Ainos, Inc.